A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients

NCT06514807 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

117

Enrollment

INDUSTRY

Sponsor class

Conditions

Essential Thrombocythaemia

Interventions

DRUG: Ropeginterferon alfa-2b (BESREMi®)

Sponsor

AOP Orphan Pharmaceuticals AG